Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer - Wikidata - wikimedia - TriplyDB

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer

http://www.wikidata.org/entity/Q36972551

about

Maximising the potential of AKT inhibitors as anti-cancer treatments Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndrome New Horizons for Precision Medicine in Biliary Tract Cancers.Signaling pathways as therapeutic targets in biliary tract cancer.Novel investigational therapies for treating biliary tract carcinoma.Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications.Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression.AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.Curcuminoid EF24 enhances the anti-tumour activity of Akt inhibitor MK-2206 through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer.New molecular and immunotherapeutic approaches in biliary cancer.Emerging role of precision medicine in biliary tract cancers

P2860

Q28072254-3E5A10E0-DF87-44A6-B1BA-88F7EDDD7D4D Q33766729-AAC2AF48-BDCC-4686-9CD1-1C3B21679CAA Q37198789-364BB7EA-00C2-4E31-B52F-67A6B28D84A9 Q38619219-96460961-5921-403D-AC99-5A9CAB27C977 Q38747573-136C6F28-7329-4A6B-9843-455735C1FA7B Q38799963-85ABF1F5-7B02-49E4-A521-5249ADD90860 Q39289707-F0A84696-514F-4C65-8068-338CB60E0DE5 Q48120617-A30357BC-0457-48D7-91C9-70AC0CE642CE Q51736090-68827332-86F8-4D2C-8D18-8785AFC42C8A Q52784526-2B263FFF-4622-4F33-A36D-74D05DF2C050 Q54476966-5C55526A-76B5-4EBB-9022-E81955946066 Q57298169-6C163DE9-6FCB-48A3-9674-DC6C34F0C985

P2860

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer

http://www.wikidata.org/entity/Q36972551

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Results of an abbreviated phas ...... s with Advanced Biliary Cancer

@en

type

label

Results of an abbreviated phas ...... s with Advanced Biliary Cancer

@en

prefLabel

Results of an abbreviated phas ...... s with Advanced Biliary Cancer

@en

P1433

Q36972551-2878246E-E9BC-4B3F-A9B0-CD421C2BAE55

P1476

Q36972551-4314B5DC-5EF5-4D70-8D77-BE32846BDF1E

P2093

Q36972551-0209ED5B-091A-400E-B78A-6CF4BA0CE584

Q36972551-101F7289-5B64-4481-85B8-413F4A80CE10

Q36972551-60F4B4D9-CF76-453E-B728-21AEA08C9D3F

Q36972551-8617ED93-9D4C-4DA2-BAF5-E7C31450D2F6

Q36972551-8EB91E18-6251-411E-909D-B5DC390A4B7F

Q36972551-91684205-F4D3-49FA-B527-BEE64E2A6F05

Q36972551-91E45089-916E-4490-99C0-BAC9E0AB08A1

Q36972551-96462816-77AC-485D-BFFE-6F88396D8E0F

Q36972551-A08FD507-2C0E-4128-8A33-4F10566A6375

P2860

Q36972551-22BED2EE-28CF-4C3D-B3ED-A5CB51D3DD03

Q36972551-33781177-40C0-4B9D-875D-6E179F388134

Q36972551-3392A8CA-9871-47A7-AECD-B66E225E8BC0

Q36972551-352F85B9-71B2-4326-ACBD-538A6FBE521C

Q36972551-3ADD38E7-2C78-4894-8A4D-E48547E136EE

Q36972551-3D112BB8-F22D-4F49-B42A-6971E8B9803F

Q36972551-6050558D-FEDC-40F3-84F1-961A137FB28C

Q36972551-66992BE5-07E7-45B3-A675-2C1E3709318A

Q36972551-68389E29-92B7-4AA4-9B1B-2A4B8CFCDE59

Q36972551-7896D9AA-E6B4-45DD-8045-C5949F4A4A1D

P2888

Q36972551-EB3DB15C-6B1E-4682-9A8A-115199188DA4

P304

Q36972551-3DEC6844-7B71-4C61-9B29-13504FA4AC94

P31

Q36972551-2723B615-36DD-4D75-A56C-7AA0BC751F53

P356

Q36972551-0E030426-78F2-437D-8D40-53D80D8334CC

P407

Q36972551-28DC978E-E0B1-4BDF-8900-AE33CB01BE33

P478

Q36972551-CDC64CDD-C0D7-4C85-AC50-F391AD5E8033

P50

Q36972551-0B908299-6373-4BB1-9202-E34524B40766

Q36972551-2B583DE2-787A-4CE0-860A-56EBB8CA7BC7

P577

Q36972551-32831FB8-C33B-4906-8EB1-86E01585B88B

P5875

Q36972551-E49FB1C4-5606-4DA8-B823-73DA9A1EC4EE

P698

Q36972551-CF46EF6F-BE7B-4CAD-B416-57929585D2AD

P932

Q36972551-F018D5C2-D1BC-4F14-A95B-5C32FDD8C7A1

P356

P1433

Scientific Reports

P1476

Results of an abbreviated phas ...... s with Advanced Biliary Cancer

@en

P2093

Austin Doyle

http://www.w3.org/2001/XMLSchema#string

Daniel H Ahn

http://www.w3.org/2001/XMLSchema#string

John L Marshall

http://www.w3.org/2001/XMLSchema#string

Junan Li

http://www.w3.org/2001/XMLSchema#string

Lai Wei

http://www.w3.org/2001/XMLSchema#string

Larry J Schaaf

http://www.w3.org/2001/XMLSchema#string

Miguel A Villalona-Calero

http://www.w3.org/2001/XMLSchema#string

Mitch A Phelps

http://www.w3.org/2001/XMLSchema#string

Tanios Bekaii-Saab

http://www.w3.org/2001/XMLSchema#string

P2860

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo

Exploiting the PI3K/AKT pathway for cancer drug discovery

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.

Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

P2888

P304

12122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP12122

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Tanios Bekaii-Saab

P577

2015-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280023742

http://www.w3.org/2001/XMLSchema#string

P698

26161813

http://www.w3.org/2001/XMLSchema#string

P932

4894406

http://www.w3.org/2001/XMLSchema#string